Safety of low-intensity extracorporeal shock wave therapy in prostate disorders: in vitro and in vivo evidence
Asian Journal of Andrology · 2024
DOI: 10.4103/aja202448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Andrology, 2024. Verfasst von Yi-Ran Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou Un…. Hauptthemen laut MEDLINE: Extracorporeal Shockwave Therapy, Cell Proliferation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Recent evidence suggests that low-intensity extracorporeal shock wave therapy (Li-ESWT) is a promising treatment for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS); however, its safety in pelvic organs, particularly prostate tissues and cells, remains unclear. The current study evaluates the risks of prostate cell damage or oncogenesis following the administration of Li-ESWT for prostatitis. To this end, a robust in vitro model (Cell Counting Kit-8 [CCK-8] assay, clone formation assay, cell scratch assay, lactate dehydrogenase [LDH] release assay, flow cytometry, and immunoblotting assay) was designed to examine the effects of Li-ESWT on cell proliferation, clonogenicity, migration, membrane integrity, and DNA damage. Exome sequencing of Li-ESWT-treated cells was performed to determine the risk of carcinogenesis. Furthermore, an in vivo rat model ( n = 20) was employed to assess the effects of Li-ESWT on cancer biomarkers (carcinoembryonic antigen [CEA], Ki67, proliferating cell nuclear antigen [PCNA], and gamma-H2A histone family member X, phosphorylation of the H2AX Ser-139 [ γ -H2AX]) in prostate tissue. Based on our findings, Li-ESWT promotes cellular growth and motility without inducing significant cell membrane or DNA damage or alterations. Genetic analyses did not demonstrate an increase in mutations, and no damage to prostate tissue or upregulation of cancer biomarkers was detected in vivo. This comprehensive in vitro and in vivo assessment confirms the safety of Li-ESWT in managing prostate disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou 730000, China.
- Department of Urology, Gansu Provincial Hospital, Lanzhou 730000, China.
- Department of Radiotherapy, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
- Department of Urology, Gansu Provincial Second People's Hospital, Lanzhou 730000, China.
Zitieren
APA
Wang, Y. R., Feng, B., Qi, W. B., Gong, Y. W., Kong, X. B., Cheng, H., Dong, Z. L., Tian, J. Q., & Wang, Z. P. (2024). Safety of low-intensity extracorporeal shock wave therapy in prostate disorders: in vitro and in vivo evidence. Asian Journal of Andrology. https://doi.org/10.4103/aja202448
Vancouver
Wang YR, Feng B, Qi WB, Gong YW, Kong XB, Cheng H, et al. Safety of low-intensity extracorporeal shock wave therapy in prostate disorders: in vitro and in vivo evidence. Asian Journal of Andrology. 2024. doi:10.4103/aja202448
BibTeX
@article{Wang2024,
author = {Wang, Yi-Ran and Feng, Bin and Qi, Wen-Bo and Gong, Yu-Wen and Kong, Xiang-Bin and Cheng, Hui and Dong, Zhi-Long and Tian, Jun-Qiang and Wang, Zhi-Ping},
title = {Safety of low-intensity extracorporeal shock wave therapy in prostate disorders: in vitro and in vivo evidence},
journal = {Asian Journal of Andrology},
year = {2024},
doi = {10.4103/aja202448}
}
EUVIMED